Heart Failure Association consensus meeting report Update on heart failure Important changes occurred since the publication of the last guidelines on heart failure (HF). Seferovic et al. 1 summarized in a consensus document the major advances that occurred in HF treatment. These include the effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus, MitraClip for functional mitral regurgitation, atrial fibrillation (AF) ablation in HF, tafamidis in cardiac transthyretin amyloidosis, rivaroxaban in HF in sinus rhythm, implantable cardioverter-defibrillators (ICD) in non-ischaemic HF and telemedicine. Epidemiology and prevention Geographic differences Tromp et al. 2 reviewed geographic differences in aetiology, co-morbidities, use of guideline-directed medical therapies, use of devices and outcomes, among HF patients from different geographic areas. They reported also the role of socioeconomic determinants, such as country income level and out-of-pocket costs, for quality of care and clinical outcomes across different countries.